News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Francis Cook: Gallipoli: The Scale Of Our War – First Look

Te Papa today allowed media access to their new exhibition Gallipoli: The Scale of Our War . The exhibition was curated with help from Weta Workshop to deliver an immersive, realistic and even disorienting experience. More>>

ALSO:

Bats Theatre: Letters From The Front Brings ANZAC Letters Alive

Inspired by centenary commemorations, improv troupe Best on Tap is producing a show based on real-life letters sent to and from New Zealand soldiers in the First World War. More>>

ALSO:

Publishing: Unity Books On Plan To Close Te Papa Press

Unity Books is alarmed that Te Papa is proposing to suspend publishing by Te Papa Press for 4 or 5 years. Te Papa Press has proven time and time again that it has both award and bestseller capability and fulfils its kaupapa. More>>

ALSO:

Cinema: ‘The Desk’ Featuring Paul Henry To Have NZ Debut

The Documentary Edge Festival is thrilled to announce The Desk as a late entry to its 2015 Programme. The film, featuring local broadcaster Paul Henry, will have its international premiere on May 21 at 10pm at Q Theatre (book now at qtheatre.co.nz) with limited screenings also on offer in Wellington and Auckland. More>>

ALSO:

Art: Considering Feminisms In Aotearoa New Zealand: Two Projects

Feminism is something that has changed our lives. Recently, the activist Marilyn Waring reviewed the impact of feminism in Aotearoa New Zealand and reminded us that just 40 years ago banks wouldn’t lend women money without the guarantee of a man, ... More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news